Company Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 06:38:53 21/01/2026 pm IST			5-day change	1st Jan Change
546.60 ^CHF	+0.55%		-1.97%	+1.71%

14/01	Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
18/12	Swiss trade surplus at CHF 3.841 bln in November	RE

Business description: Lonza Group AG

Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows:

- bio-pharmaceuticals (57.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.;

- capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (16.5%). In addition, the group offers nutritional ingredients;

- small molecule drug substances (15.3%);

- technologies and platforms for manufacturing processes and production of cell and gene therapies (10.8%).

Number of employees: 19,299

Sales by Activity: Lonza Group AG

Fiscal Period: December	2020 (CHF)	2021 (CHF)	2022 (CHF)	2023 (CHF)	2024 (CHF)
Biologics	-	272.5Cr	328Cr	372.4Cr	368Cr
Advanced Synthesis	-	77Cr	82Cr	90Cr	98Cr
Specialized Modalities	-	65Cr	74Cr	76Cr	74Cr
Pharma Biotech & Nutrition	449.8Cr	-	-	-	-
Capsules & Health Ingredients	-	122Cr	126.9Cr	116.2Cr	105.5Cr
Corporate/Eliminations	1Cr	4.2Cr	11Cr	17Cr	11Cr

See all business segments

Geographical breakdown of sales: Lonza Group AG

Fiscal Period: December	2020 (CHF)	2021 (CHF)	2022 (CHF)	2023 (CHF)	2024 (CHF)
United States	256.8Cr	211.7Cr	241.5Cr	213.6Cr	230.9Cr
Switzerland	64Cr	66Cr	100Cr	116.8Cr	72Cr
Belgium	38Cr	20Cr	30Cr	34Cr	47Cr
Ireland	26Cr	40Cr	34Cr	37Cr	46Cr
Japan	22Cr	21Cr	23Cr	54Cr	44Cr
Germany	22Cr	20Cr	22Cr	30Cr	30Cr
Denmark	12Cr	13Cr	16Cr	32Cr	28Cr
United Kingdom	18Cr	17Cr	14Cr	17Cr	24Cr
Rest of Europe	9.5Cr	22Cr	21Cr	20Cr	18Cr
Netherlands	5.6Cr	7.6Cr	13Cr	8.8Cr	17Cr
China	25Cr	14Cr	16Cr	17Cr	15Cr
South Korea	11Cr	7.9Cr	14Cr	9.7Cr	12Cr
France	24Cr	9.7Cr	12Cr	11Cr	11Cr
Sweden	16Cr	14Cr	14Cr	12Cr	11Cr
Canada	8.4Cr	8.2Cr	6.3Cr	9Cr	10Cr
Rest of Latin America	2.8Cr	4.7Cr	3.8Cr	2.6Cr	8Cr
Italy	2.8Cr	3.8Cr	4.1Cr	5.2Cr	6Cr
Brazil	6.4Cr	6Cr	4.9Cr	7.1Cr	4.9Cr
India	6.9Cr	4Cr	4.2Cr	4.2Cr	4.6Cr
Spain	2.6Cr	4.4Cr	4.1Cr	4Cr	4.1Cr
Singapore	7.8Cr	14Cr	11Cr	14Cr	3.2Cr
Mexico	4.7Cr	3Cr	3.4Cr	3.3Cr	3.1Cr
Rest of Asia	6.8Cr	3.1Cr	3.6Cr	2.9Cr	2.8Cr
Australia & New Zealand	7.5Cr	1.7Cr	2.1Cr	1.6Cr	1.7Cr
Indonesia	3.2Cr	1.8Cr	1.6Cr	1.4Cr	1.2Cr
Thailand	3.8Cr	1.7Cr	1.5Cr	1.5Cr	1.2Cr
Czech Republic	60L	70L	70L	1.1Cr	80L
Other Countries	1.7Cr	10L	20L	20L	30L
Africa	1.6Cr	-	-	-	-
Rest of North and Central America	1.3Cr	10L	10L	10L	-

See all geographic segments

Executive Committee: Lonza Group AG

Manager	Title	Age	Since
Wolfgang Wienand CEO	Chief Executive Officer	54	01/07/2024
Philippe Deecke DFI	Director of Finance/CFO	54	01/12/2021
Daniel Buchta IRC	Investor Relations Contact	-	-
Andreas Bohrer LAW	General Counsel	-	01/01/2015
Maria Nunez COO	Chief Operating Officer	57	01/08/2022

See LONZA GROUP AG governance

Composition of the Board of Directors: Lonza Group AG

Director	Title	Age	Since
Barbara Richmond BRD	Director/Board Member	65	16/04/2014
Jürgen B. Steinemann BRD	Director/Board Member	68	16/04/2014
Christoph Mäder BRD	Director/Board Member	66	26/04/2016
Angelica Kohlmann BRD	Director/Board Member	66	04/05/2018
Marion Helmes BRD	Director/Board Member	60	05/05/2022
Roger Nitsch BRD	Director/Board Member	65	01/05/2022
R. Jean-Marc Sidney Huët CHM	Chairman	57	08/05/2024
Juan Andres BRD	Director/Board Member	61	09/05/2025
Eric Drapé BRD	Director/Board Member	64	09/05/2025
David Meline BRD	Director/Board Member	68	09/05/2025

Composition of the Board of Directors

Shareholders: Lonza Group AG

Name	Equities	%	Valuation
Norges Bank Investment Management 3.085 %	21,66,785	3.085 %	1 473 M CHF
LONZA GROUP AG 3.075 %	21,59,562	3.075 %	1 468 M CHF
Nordea Investment Management AB 0.287 %	2,01,555	0.287 %	137 M CHF
Rathbones Asset Management Ltd. 0.2812 %	1,97,460	0.2812 %	134 M CHF
Capfi Delen Asset Management NV 0.2227 %	1,56,401	0.2227 %	106 M CHF

Name	Equities	%	Valuation
SBI Funds Management Ltd. 0.0342 %	2,40,000	0.0342 %	16 M CHF
Azimuth Capital Investment Management LLC 0.0199 %	1,39,435	0.0199 %	9 M CHF
Zevin Asset Management LLC 0.0187 %	1,31,336	0.0187 %	9 M CHF
Torray Investment Partners LLC 0.0138 %	97,095	0.0138 %	7 M CHF
Domini Impact Investments LLC 0.003517 %	24,700	0.003517 %	2 M CHF

List of LONZA GROUP AG shareholders

Holdings: Lonza Group AG

Name	Equities	%	Valuation
LONZA GROUP AG 3.08%	21,59,562	3.08%	1 468 M $

Company details: Lonza Group AG

Lonza Group AG

Muenchensteinerstrasse 38

4002, Basel

+41 61 316 81 11

http://www.lonza.com

Group companies: Lonza Group AG

Name	Category and Sector
Lonza India Pvt Ltd.
Lonza India Pvt Ltd.
Lonza Sales AG Lonza Sales AG Supplies pharmaceutical, biotech and specialty ingredients
Lonza Sales AG Lonza Sales AG Supplies pharmaceutical, biotech and specialty ingredients
M.W. Encap Ltd. M.W. Encap Ltd. Manufactures drugs for pharmaceutical preparations

See all subsidiaries

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
LONZA GROUP AG	+0.55%	-1.97%	-4.07%	+10.51%	4.83TCr
IQVIA HOLDINGS INC.	-1.68%	-3.26%	+18.41%	+4.51%	3.98TCr
BEONE MEDICINES AG	-1.16%	-4.78%	+59.12%	+25.47%	3.7TCr
CELLTRION, INC.	+0.24%	-6.33%	+19.14%	+39.10%	3.07TCr
REVOLUTION MEDICINES, INC.	-3.38%	-3.11%	+188.46%	+322.31%	2.25TCr
MEDPACE HOLDINGS, INC.	-1.39%	-0.99%	+78.57%	+162.90%	1.7TCr
EUROFINS SCIENTIFIC SE	-0.40%	-2.67%	+45.33%	+8.65%	1.46TCr
Average	-0.16%	-3.01%	+57.85%	+81.92%	3TCr
Weighted average by Cap.	-0.15%	-3.15%	+45.46%	+61.77%